BioNTech SE
Open
$104.25
Prev. Close
$104.26
High
$104.26
Low
$104.22
Market Snapshot
$24.42B
-18.4
-3.00
$2.96B
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 7,807 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
emptyResult
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 7,807 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Recently from Cashu
BioNTech SE: Strong Oncology Pipeline Indicates Significant Growth Potential Amid Market Shifts
BioNTech's Promising Oncology Pipeline Signals Growth Potential BioNTech SE finds itself at a pivotal moment as Citi initiates coverage with a "buy" rating, underscoring the company's strong oncology…
BioNTech SE's Oncology Pipeline Boosts Analyst Confidence and Growth Potential
BioNTech’s Promising Oncology Pipeline Sparks Analyst Optimism In a significant development for BioNTech SE, Citi has initiated coverage of the company with a "buy" rating, underscoring the potential…
BioNTech SE Positioned for Growth Amid Biotech Sector's Anticipated Recovery
Biotech Sector Poised for Recovery Amidst Challenges The biotech industry appears on the cusp of a resurgence, as experts predict renewed activity and interest in the sector following years of underpe…